Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System

Sponsor
Huashan Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT04311398
Collaborator
(none)
100
1
6.6
15.1

Study Details

Study Description

Brief Summary

Our project intends to independently develop a fully enclosed rapid detection system for a total of 22 pathogens, including SARS-CoV-2, on the basis of the QIAstat-Dx fully automatic multiple PCR detection platform. The reasonably designed experiments are used to verify the performance of the cartridge detection and prove its clinical application value. The 22 pathogens tested in this project includes 4 coronavirus subtypes, A / B flu, parainfluenza virus, respiratory syncytial virus, etc., which is of great significance for the differential diagnosis of similar patients.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: New QIAstat-Dx fully automatic multiple PCR detection platform

Detailed Description

COVID-19 has not been well suppressed, and became a pandemic within 3 months globally is mainly because of the virus characteristic in the following aspects:

  1. Long incubation period (average 5-7 days, up to 28 days), and the incubation period is contagious

  2. Strong transmissibility, virus can be transmitted through aerosol

  3. Difficulty distinguishing infected patients from other pathogenic infections

  4. High negative rate of nucleic acid detection in upper respiratory tract samples of infected patients, which increases the difficulty of differential diagnosis of infection with other pathogens The existing RT-PCR nucleic acid detection kits for SARS-CoV-2 has two major problems. First, the procedure is not automated leading to higher requirements for personnel operation level and environment sterilize. What's more the kits are SARS-CoV-2 only. Once the test result is negative, it cannot help diagnose the exact pathogen in one time of experiment.

Therefore, this project intends to independently develop a fully enclosed rapid detection system for a total of 22 pathogens, including SARS-CoV-2, on the basis of the QIAstat-Dx fully automatic multiple PCR detection platform. The reasonably designed experiments are used to verify the performance of the cartridge detection and prove its clinical application value. The 22 pathogens tested in this project includes 4 coronavirus subtypes, A / B flu, parainfluenza virus, respiratory syncytial virus, etc., which is of great significance for the differential diagnosis of similar patients.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System
Anticipated Study Start Date :
May 13, 2020
Anticipated Primary Completion Date :
Jun 1, 2020
Anticipated Study Completion Date :
Dec 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Respiratory infection group

Patients went to fever clinic with respiratory infectious symptoms in Huashan Hospital affiliated to Fudan University

Diagnostic Test: New QIAstat-Dx fully automatic multiple PCR detection platform
We use the New QIAstat-Dx fully automatic multiple PCR detection platform to test the enrolled patients

Outcome Measures

Primary Outcome Measures

  1. Sensitivity, spectivity turnaround time of the New QIAstat-Dx fully automatic multiple PCR detection platform [3 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients went to the fever clinic with respiratory infectious symptoms
Exclusion Criteria:
  • none

Contacts and Locations

Locations

Site City State Country Postal Code
1 Huashan Hospital of Fudan University Shanghai Shanghai China 200040

Sponsors and Collaborators

  • Huashan Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Wen-hong Zhang, Chief of dpartment of infectious disease, Huashan Hospital
ClinicalTrials.gov Identifier:
NCT04311398
Other Study ID Numbers:
  • KY2020-COVID-19
First Posted:
Mar 17, 2020
Last Update Posted:
May 14, 2020
Last Verified:
May 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 14, 2020